Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yasuhiro Oki

Showing results (31-40 of 164) with videos related to

Pageof 17
Sort By:
Leukemia & Lymphoma|July 13, 2011
Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: analyses with competing risk regression modelDai Chihara, Yasuhiro Oki, Keitaro Matsuo, et al.
Bioorganic & Medicinal Chemistry|August 29, 2017
Lipase-catalyzed asymmetric synthesis of naphtho[2,3-c]furan-1(3H)-one derivatives by a one-pot dynamic kinetic resolution/intramolecular Diels-Alder reaction: Total synthesis of (-)-himbacineKoji Sugiyama, Shinji Kawanishi, Yasuhiro Oki, et al.
European Journal of Haematology|August 12, 2008
Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximabYasuhiro Oki, Kazuhito Yamamoto, Harumi Kato, et al.
Haematologica|July 28, 2006
Mutations and promoter methylation status of NPM1 in myeloproliferative disordersYasuhiro Oki, Jaroslav Jelinek, Miloslav Beran, et al.
Cancer|June 24, 2005
Phase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphomaYasuhiro Oki, Peter McLaughlin, Barbara Pro, et al.
Blood|March 3, 2012
Experience with obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphomaYasuhiro Oki, Amanda Copeland, Fredrick Hagemeister, et al.
Leukemia & Lymphoma|May 3, 2008
Prognostic value of serum soluble interleukin-2 receptor level in patients with diffuse large B cell lymphoma, treated with CHOP- or RCHOP-based therapyYasuhiro Oki, Harumi Kato, Keitaro Matsuo, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 8, 2011
Interstitial pneumonia after autologous hematopoietic stem cell transplantation in B-cell non-hodgkin lymphomaHarumi Kato, Kazuhito Yamamoto, Hirofumi Taji, et al.
Blood|May 23, 2015
Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphomaChan Yoon Cheah, Loretta J Nastoupil, Sattva S Neelapu, et al.
European Journal of Haematology|February 13, 2010
Primary gastric diffuse large B-cell Lymphoma (DLBCL): analyses of prognostic factors and value of pretreatment FDG-PET scanDai Chihara, Yasuhiro Oki, Shouji Ine, et al.
Pageof 17

Showing results (31-40 of 164) with videos related to

Sort By:
Pageof 17
Leukemia & Lymphoma|July 13, 2011
Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: analyses with competing risk regression modelDai Chihara, Yasuhiro Oki, Keitaro Matsuo, et al.
Bioorganic & Medicinal Chemistry|August 29, 2017
Lipase-catalyzed asymmetric synthesis of naphtho[2,3-c]furan-1(3H)-one derivatives by a one-pot dynamic kinetic resolution/intramolecular Diels-Alder reaction: Total synthesis of (-)-himbacineKoji Sugiyama, Shinji Kawanishi, Yasuhiro Oki, et al.
European Journal of Haematology|August 12, 2008
Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximabYasuhiro Oki, Kazuhito Yamamoto, Harumi Kato, et al.
Haematologica|July 28, 2006
Mutations and promoter methylation status of NPM1 in myeloproliferative disordersYasuhiro Oki, Jaroslav Jelinek, Miloslav Beran, et al.
Cancer|June 24, 2005
Phase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphomaYasuhiro Oki, Peter McLaughlin, Barbara Pro, et al.
Blood|March 3, 2012
Experience with obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphomaYasuhiro Oki, Amanda Copeland, Fredrick Hagemeister, et al.
Leukemia & Lymphoma|May 3, 2008
Prognostic value of serum soluble interleukin-2 receptor level in patients with diffuse large B cell lymphoma, treated with CHOP- or RCHOP-based therapyYasuhiro Oki, Harumi Kato, Keitaro Matsuo, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 8, 2011
Interstitial pneumonia after autologous hematopoietic stem cell transplantation in B-cell non-hodgkin lymphomaHarumi Kato, Kazuhito Yamamoto, Hirofumi Taji, et al.
Blood|May 23, 2015
Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphomaChan Yoon Cheah, Loretta J Nastoupil, Sattva S Neelapu, et al.
European Journal of Haematology|February 13, 2010
Primary gastric diffuse large B-cell Lymphoma (DLBCL): analyses of prognostic factors and value of pretreatment FDG-PET scanDai Chihara, Yasuhiro Oki, Shouji Ine, et al.
Pageof 17